X-ray co-crystal structure of compound 20 with Mcl-1

The last decade of small-molecule process development has witnessed a trend of increasing molecular complexity for clinical candidates. The continued advance of novel catalytic methods and subsequent translation to efficient and scalable processes has enabled process chemists to overcome the challenges associated with increasing complexity. This Account highlights several examples from the process chemistry laboratories at Amgen.1 Introduction2 The Evolution of Molecular Complexity3 Catalysis as a Lever to Build Complexity4 Ru(II)-Catalyzed Dynamic Kinetic Resolution Enabling the Manufacture of AMG 2325 Application of Enzymatic Desymmetrization toward Scale-Up of the MCL-1 Inhibitor AMG 1766 Synthesis of Fucostatin 1: Catalytic Asymmetric Transfer Hydrogenation7 Manganese-Catalyzed Asymmetric Epoxidation To Prepare a Carfilzomib Intermediate8 Asymmetric Reduction Strategies: Novel Apelin Receptor Agonists and AMG 9869 Conclusions

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

X-ray co-crystal structure of compound 20 with Mcl-1

Cited by 4 publications

References 38 publications

The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs

The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs

Synthesis of a Macrocyclic Mcl-1 Inhibitor

Building Complexity and Achieving Selectivity through Catalysis – Case Studies from the Pharmaceutical Pipeline

Contact Info

Product

Resources

About